Treatment of progressive supranuclear palsy with autologous adipose tissue-derived mesenchymal stem cells: a case report by Soo Won Choi et al.
JOURNAL OF MEDICAL
CASE REPORTS
Choi et al. Journal of Medical Case Reports 2014, 8:87
http://www.jmedicalcasereports.com/content/8/1/87CASE REPORT Open AccessTreatment of progressive supranuclear palsy with
autologous adipose tissue-derived mesenchymal
stem cells: a case report
Soo Won Choi1, Kwon Byong Park2, Sang Kyu Woo3, Sung Keun Kang3 and Jeong Chan Ra3*Abstract
Introduction: Progressive supranuclear palsy is a relentlessly progressive neurodegenerative disorder and is clinically
characterized by parkinsonism. Adipose tissue-derived mesenchymal stem cells have recently demonstrated the
possibility of treating neurological disorders. Therefore, autologous adipose tissue-derived mesenchymal stem
cells transplantation can be an alternative method for treating progressive supranuclear palsy.
Case presentation: This study was approved by the Korea Food and Drug Administration through the Emergency
Use Investigational New Drug Application. A 71-year-old Asian man from South Korea with progressive supranuclear palsy
was treated with five intravenous infusions (each time 2×108 cells) and four intrathecal infusions (each time 5×107 cells)
with autologous adipose tissue-derived mesenchymal stem cells expanded under good manufacturing practice
conditions. Clinical examinations were performed immediately before treatment and throughout the six months
of follow-up. The tests included: 1) Progressive Supranuclear Palsy Rating Scale; 2) Berg Balance Scale; 3) Korean Mini
Mental State Examination; 4) Modified Barthel Index; 5) grip strength; 6) Box and Block Test; and 7) Nine-Hole Peg Test.
The Progressive Supranuclear Palsy Rating Scale results gradually decreased, and the clinical rating scale scores of the
Berg Balance Scale, Korean Mini Mental State Examination, and Modified Barthel Index gradually increased. Grip
strength was maintained. Performance in the Box and Block Test and Nine-Hole Peg Test improved after adipose
tissue-derived mesenchymal stem cells treatment compared to baseline throughout the six months of follow-up.
Except for the intermittent mild fever and transient elevated blood pressure, the treatment of our patient with
progressive supranuclear palsy with autologous adipose tissue-derived mesenchymal stem cells showed no
significant adverse events, and delayed the progression of neurological deficits by achieving functional improvement
in the follow-up period.
Conclusions: These results are encouraging and hopeful for further studies in patients with progressive supranuclear
palsy using autologous adipose tissue-derived mesenchymal stem cells as a safe and effective therapy. This case
report is the first known study of adipose tissue-derived mesenchymal stem cells safely delaying the progression
of progressive supranuclear palsy with functional improvement during the follow-up period.
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Progressive supranuclear palsy (PSP) is a late-onset neu-
rodegenerative disease and one of a number of diseases
collectively referred to as atypical parkinsonian disorders
(APDs) including multiple system atrophy (MSA), demen-
tia with Lewy bodies, and corticobasal degeneration [1,2].
The prevalence of PSP has been estimated at 1.39 to
6.4 per 100,000 [3,4], although this is likely to be an
underestimate because of diagnostic confusion with idio-
pathic Parkinson’s disease based on the clinical similarity
of phenotypes such as slow movements and gait difficulty.
The clinical features are atypical, and diagnosis is often
delayed or not made during the lifespan of the patient.
PSP also represents at least 5 percent of patients who
manifest parkinsonian symptoms [5]. However, this per-
centage is probably an underestimate due to the difficulties
in diagnosing this syndrome [1,4].
Success in treating patients with PSP remains exceed-
ingly low [6]. Dopaminergic drugs are regularly used for
the parkinsonian features, but benefit is poor or transient
[1,7,8]. No drug treatment consistently treats PSP patients
in the long term, and neuroprotective or regenerative
strategies may be invaluable in the management of
patients with PSP [6]. Recently, accumulating evidence
indicates that mesenchymal stem cells (MSCs) can be
an alternative therapy for PSP. The treatment of MSCs
had neuroprotective and neuroregenerative effects with
idiopathic or APDs in animal [9] and human [10] studies.
Therefore, recent evidence suggests that MSC treatment
can be a novel therapy for treating PSP. This is the first
case report that describes the efficacy of systemic and
intrathecal infusion of autologous adipose tissue-derived
MSCs (AdMSCs) for a patient with PSP.
Case presentation
This study was approved by the Korea Food and Drug
Administration with Emergency Use Investigational New
Drug Application number CTMD (Clinical Trials Man-
agement Division) -2440 and the Institutional Review
Board (No. 2012-03-RNL-ASTROSTEM). Prior to stem
cell therapy, a consent form was signed by the guardians
of the patient and they agreed to provide the medical
records for the publication of this report.
An Asian man, 71 years of age during the time of the
study, suffered from several disorders of the central ner-
vous system (CNS). When he was 56 years old, he had
severe dizziness and vomiting symptoms and was diag-
nosed with cerebral infarction. At age 58, he had postural
instability, leaning to the right side, and was diagnosed
with infarction in small vessels of the brain by a magnetic
resonance imaging (MRI) scan. In addition, he had urinary
incontinence and difficulty with emotional control. When
he was 65 years old, he fell on his right side. In that same
year, his gait and dysarthria worsened along with his reflexcoughing during fluid intake. He was diagnosed with
Parkinson’s syndrome and began taking Sinemet® (carbi-
dopa 50mg + levodopa 200mg). After no response, he
stopped taking Sinemet®. He received rehabilitation
treatment occasionally, yet the symptoms continued. At
71 years of age, he was diagnosed with PSP by a brain
positron emission tomography - computed tomography
(PET-CT) scan. He took Madopar® (benserazide 50mg +
levodopa 200mg) for medication. After no response, he
stopped taking the drug. He took aspirin (100mg/daily),
Plavix® (clopidogel 37.5mg/daily), and Norvasc® (amlodipine
besylate 5mg/daily) starting immediately after the lack of
response to medication became apparent and continued
during and after the autologous AdMSCs treatments were
administered.
Our patient was subjected to hematology and serological
tests for liver and renal function prior to the collection
of subcutaneous fat from the abdomen via liposuction.
His hematology and serological test results were normal.
Our patient was not infected with syphilis, human im-
munodeficiency virus, hepatitis B, or hepatitis C. AdMSCS
were isolated, expanded, and analyzed, as previously
described in detail [11], according to good manufacturing
practice (GMP) conditions. Multiple AdMSC aliquots
were prepared at passage 2 and stored in liquid nitrogen
vapor. Cryopreserved cells were thawed and recultured
in growth medium according to the infusion schedule
(see below). Cells were harvested at passage 3, and the
quality control tests, including cell viability and for fungal,
bacterial, endotoxin, and mycoplasma contamination, were
carried out before infusion. No evidence of bacterial, fungal,
or mycoplasma contamination was observed.
For 12 weeks, he was treated with five intravenous
infusions, each containing 2×108 autologous AdMSCs
(1×108 cells/100ml normal saline), via the cephalic vein
for about 2 hours (a total of 109 cells via intravenous
infusion) [11] and four intrathecal injections, each con-
taining 5×107AdMSCs in 2ml of normal saline, via a
standard lumbar puncture (a total of 2×108 cells via
intrathecal injection). The patient received rehabilitation
therapy after the fourth treatment for 12 weeks.
Safety was monitored extensively on day 0, week 2,
week 4, month 2, month 3 and month 6 for tolerance,
adverse events, laboratory tests, physical examinations,
and vital signs. The clinical improvement was evaluated
on the beginning of the first treatment (day 0), and on
month 1, month 3, and month 6 of follow-up.
Safety and tolerability were assessed on the basis of
hematological and biochemical tests highlighting values
outside the normal range, medical examination findings,
and adverse event reporting. After AdMSCs infusion,
intermittent mild fever (37.8 to 38.5°C) was observed
during the second, fourth, and fifth treatments. His blood
pressure was elevated to 200/123mmHg with intermittent
Figure 1 The change of clinical rating scale scores from baseline
throughout the six months of follow-up. The Progressive
Supranuclear Palsy Rating Scale score gradually decreased and the
clinical rating scale scores of the Berg Balance Scale, Korean Mini
Mental State Examination, and Korean Modified Barthel Index
gradually increased. D, day; M, month.
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his body temperature was over 38°C, Dicknol (diclofe-
nac-β-dimethyl-aminoethanol, 90mg) was administered
intramuscularly. Betasin (labetalol 20mg) was injected
intravenously for elevated blood pressure. The adverse
effects disappeared immediately after Dicknol or Betasin
treatment. Except for the intermittent mild fever and the
one-time elevation of his blood pressure, there were no
significant adverse events during and following autologous
AdMSCs treatments.
The results of his clinical assessment are summarized
in Table 1 and Figure 1. As shown in Table 1 and Figure 1,
the Progressive Supranuclear Palsy Rating Scale (PSPRS)
score gradually decreased from 69 to 63 points throughout
the six months of follow-up after AdMSC treatment. The
clinical rating scale scores gradually increased from 3
to 9 points in the Berg Balance Scale (BBS), from 15 to
17 points in the Korean Mini Mental State Examination
(K-MMSE), and from 7 to 21 points in the Modified
Barthel Index (MBI) throughout the six months of
follow-up after AdMSC treatment compared to baseline
(Table 1 and Figure 1). The grip strength, Box and
Block Test (BBT), and Nine-Hole Peg Test (NHPT) were
also performed to measure the strength or functional
performance of the upper limbs. The grip strength was
maintained from 8 to 8kg on his right hand and increased
from 8 to 10kg on his left hand (Table 1 and Figure 2)
after stem cell treatment. His results improved from 9 to
14 numbers of blocks transported on his right hand and
from 13 to 16 numbers of blocks transported on his left
hand during BBT (Table 1, Figure 3). Throughout the six
months of follow-up, in NHPT, he performed faster, and
the run time was shortened from 202 to 79 seconds on his
right hand and from 127 to 94 seconds on his left hand
(Table 1, Figure 4) after AdMSC treatment compared to
baseline.Table 1 Clinical assessments between pre- and
post-treatments of autologous adipose tissue-derived
mesenchymal stem cells (AdMSCs) in a patient with
progressive supranuclear palsy (PSP) throughout the
six months of follow-up
Day 0 Month 1 Month 3 Month 6
PSPRS (/Total 100 points) 69 71 65 63
BBS (/Total 56 points) 3 3 7 9
K-MMSE (/Total 30 points) 15 14 19 17
MBI (/Total 100 points) 7 9 15 21
Grip strength (Kg, R/L) 8/8 1/8 9/18 8/10
BBT (Numbers, R/L) 9/13 9/14 14/15 14/16
NHPT (Seconds, R/L) 202/127 182/95 100/48 79/94
PSPRS, Progressive Supranuclear Palsy Rating; BBS, Berg Balance Scale;
K-MMSE, Korean Mini Mental State Examination; MBI, Modified Barthel Index;
BBT, Box and Block Test; NHPT, Nine-Hole Peg Test.Discussion
PSP is a rare disease with rapidly progressive disabling
neurological function and is fatal within 10 years of onset
[12,13]. The patients' mean age at onset of PSP is typically
between 55 and 65 years with a median survival time
of 5.6 to 7.3 years [13]. The natural course of PSP is a
relentlessly progressive deterioration. One-year survival
has a rate of 70.2 percent but two-year survival has a rate
of only 28.5 percent for patients with scores from 60 to
69. One-year survival rate was 47.4 percent but two-year
survival rate was 16.4 percent for patients with scores over
70 [12]. There is no significant benefit of current therapies
for patients with PSP [12,13].
Recently, accumulating evidence indicates that MSCs
can differentiate into neural cells in vitro [11] and pro-
tect the brain in animal models from CNS injuries such
as Alzheimer’s disease [14] or Parkinson’s disease [9,10].
The adipose tissue is a very attractive source for MSCs.Figure 2 The change of grip strengths from baseline
throughout the six months of follow-up. The grip strength was
maintained after autologous adipose tissue-derived mesenchymal
stem cells treatment compared to baseline. D, day; M, month.
Figure 3 The change of box and block test (numbers) from
baseline throughout the six months of follow-up. There was
improved function of the right hand in the Box and Block Test.
D, day; M, month.
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In our animal study of Alzheimer’s disease, intraven-
ously administered human AdMSCs localized in the CNS,
differentiated into nerve cells, and protected the system
from the death of nerve cells by increasing neuroprotec-
tive agents [14]. These results present the possibility of
treating patients with PSP with MSCs. In this case report,
we used mixed administration routes of intravenous and
intrathecal. While the intrathecal route may enhance the
therapeutic effects by facilitating AdMSCs movement to
the CNS, the dosage of ASCs is limited due to the narrow
intrathecal cavity compared to intravenous administration.
Therefore, we also used the intravenous route to increase
the dosage of AdMSCs, leading to a higher efficacy.
The patient in the present study was diagnosed with
infarction of cerebral microvessels at 57 years old and has
suffered from CNS disorders for 15 years. In addition, he
had had a worsening of symptoms such as gait problems,
postural instability, urinary incontinence, emotional prob-Figure 4 The change of nine-hole peg test (seconds) from
baseline throughout the six months of follow-up. It was
performed faster and the run time was shortened. D, day; M, month.lems, and cognitive impairment during the six years since
the diagnosis of Parkinson’s syndrome, before it being con-
firmed as PSP. Our patient was treated with autologous
AdMSCs when the disease had progressed to severe
status. The safety of the autologous stem cell infusion via
both intravenous and intrathecal routes was monitored.
Hematological and biochemical tests showed no signifi-
cant adverse reactions after stem cell infusion. In line with
our results, the safety of administration of AdMSCs [11]
was reported by demonstrating that none of the patients
developed any serious adverse events related to MSC
treatment. In regard to the efficacy, after treatment with
AdMSCs, the PSPRS score was gradually decreased 6
points from baseline, and cognitive impairment and the
activities of daily living were improved throughout the
six months of follow-up. Although, our results were
for a short period of follow-up of one patient, the mul-
tiple intravenous and intrathecal infusions of autologous
AdMSCs were safe and effective in delaying the progres-
sion of the disease.
The pathophysiological knowledge of brain dysfunction,
particularly for Alzheimer’s disease, has increased over the
years. Much of this knowledge has been revealed using
current imaging techniques along with other genetic and
pathological research. This knowledge provides an under-
standing of the mechanism that leads to brain dysfunction
and disease [15]. In the current study, however, we focused
the evaluation on the safety rather than efficacy of stem
cells due to our conditions as patients with PSP are rare,
difficult to diagnosis and revealing of the neuropsycho-
logical changes. Nevertheless, to the best of our knowledge,
this clinical case is the first case report using adipose
tissue-derived mesenchymal stem cells to treat a patient
with PSP.
We believe that increasing preclinical and clinical data
on MSCs’ effect in conjunction with a more large-scale
clinical study on neurodegenerative disease will lead to a
more basal understanding of brain damage and neurode-
generative disease.
Taken together, our results with the studies of other
clinical researchers present an encouraging treatment
of autologous MSCs to those suffering from atypical
Parkinson syndrome who have a short prognosis.
Conclusions
The current results suggest that repeated infusion of
autologous AdMSCs can be a safe and effective therapy
for PSP. We anticipate that repeated administration of
an adequate number of AdMSCs will prevent further
neurological damage following the onset of PSP.
In conclusion, this is the first case report showing that
autologous AdMSCs treatment of a patient with PSP was
safe and delayed the progression of neurological deficits
by achieving functional improvement in the follow-up
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hopeful for further studies on more patients with PSP.
Consent
Written informed consent was obtained from the guardians
of the patient for publication of this case report and any
accompanying images. A copy of the written consent is
available for review by the Editor-in-Chief of this journal.
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